News
Novo Nordisk Says Its 'Wegovy In A Pill' Delivers Big: '16.6% Average' Weight Loss, Over 20% For One-Third Of Adults Struggling With Obesity
Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights early data that shows safety and efficacy figures that are similar to its injectables.
Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...
Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.
5don MSN
The company’s blockbuster drugs helped it beat Wall Street’s expectations—while WeightWatchers declares bankruptcy. One day ...
Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be ...
Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.
GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening steatohepatitis.
Novo Nordisk stock rose after the Danish pharma giant posted better-than-expected quarterly earnings even as sales of its ...
Novo Nordisk's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback